Relationship between bone scintigraphy and tumor markers in patients with breast cancer

Annals of Nuclear Medicine

Volumn 18, Issue 6, 2004, Pages 501-505

  Yildiz, Mustafa ^a,d   Oral, Baha ^a   Bozkurt, Mehmet ^b   Cobaner, Azem ^c  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISPARTA STATE HOSPITAL   (Turkey)

^c Sinyal Nuclear Medicine Center   (Turkey)

^d Istiklal Mah   (Turkey)

Author keywords

Bone scintigraphy; Breast cancer; Breast cancer associated antigen (CA 15 3); Carcinoembryonic antigen (CEA)

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MEDRONATE TECHNETIUM TC 99M; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 6944241142     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984567     Document Type: Article

References (15)

1. Coleman RE, Rubens RD. The clinical course of bone metastasis from breast cancer. Br J Cancer 1987; 55: 61-66.
2. Coleman RE, Rubens RD, Fogelman I. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med 1988; 29: 1045-1049.
3. Crippa F, Bombardieri E, Seregni M, et al. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastasis of breast cancer. J Nucl Biol Med 1992; 36: 52-55.
4. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastasis in breast cancer patients with equivocal bone scintigraphy. Br J Cancer 1999; 79: 1443-1447.
5. Zanco P, Rota G, Sportiello V, et al. Diagnosis of bone and liver metastasis in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers 1989; 4: 103-105.
6. O'Brien DP, Horgan PG, Gough DB, et al. CA 15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl 1992; 74: 9-11.
7. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38: 1189-1193.
8. Forest JC, Masse J, Lane A. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys 2010 immunoanalyzer. Clin Biochem 1998; 31 (2): 81-88.
9. Koizumi M, Yamada Y, Takiguchi T, et al. Bone metabolic markers in bone metastasis. J Cancer Res Clin Oncol 1995; 121: 542-548.
10. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastasis. Bone 1991; 12: 9-10.
11. Cook GJR, Fogelman I. Skeletal metastasis from breast cancer: Imaging with Nuclear Medicine. Semin Nucl Med 1999; 29: 69-79.
12. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843-2877.
13. Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comperative study with carcinoembryonic antigen. Cancer 1991; 68: 574-582.
14. Buffaz PD, Gauchez AS, Caravel JP, et al. Can tumor marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999; 26: 8-11.
15. Younsi N, Montravers F, Philippe C, et al. CA 15-3 and bone scintigraphy in the follow-up of breast cancer. Int J Biol Markers 1997; 12: 154-157.